News and Events – COD Research

WDSC-Web-Upcoming

4 months ago

WDSC upcoming

Posted by cppl_codresearch_2022

Bio-2024-Attendee-Web-01_ Upcoming

Bio 2024 upcoming

World Drug safety Congress Europe 2023 in Amsterdam, Netherlands

DIA 2023 in Boston, Massachusetts

CODE Exhibiting at BIO 2024

DCAT 2023 in New York City

Scope 2023 in Orlando, Florida

Events

2 years ago

Pharmacovigilance System guideline of South Africa – A high level glance

Events

2 years ago

COD research is delighted to present on “Career Opportunities in Pharmacovigilance”

Events

2 years ago

An insightful session on “ISO: 14155- Introduction to Clinical Investigation for Medical Devices” by Dr. Ashok Thakkar

Events

2 years ago

38th International Society for Pharmacoepidemiology (ICPE)

Events

2 years ago

We are delighted to welcome Mohit Kapoor as Director – Project Management and Operations Strategy

Events

2 years ago

We are the silver sponsor at WDSC-2022

Events

2 years ago

Dr Jay Dave is among the selected speakers to give a presentation during the event.

Events

2 years ago

Experts at our Booth # 42 are awaiting your presence to unlock your Drug Safety Challenges and enhance compliance.

Events

2 years ago

CPhI Frankfurt is calling!

Events

2 years ago

COD Research USA INC is attending World Drug Safety Congress – 2022, Boston.

EMEA-003429-PIP01-23
Source: EMA Published on 2024-09-13
EMEA-003429-PIP02-23
Source: EMA Published on 2024-09-13
EMEA-003431-PIP01-23
Source: EMA Published on 2024-09-13
EMEA-002773-PIP01-20-M01
Source: EMA Published on 2024-09-13
EMEA-002699-PIP01-19-M01
Source: EMA Published on 2024-09-13
EMEA-002677-PIP01-19-M03
Source: EMA Published on 2024-09-13
EMEA-002653-PIP01-19-M01
Source: EMA Published on 2024-09-13
EMEA-002635-PIP02-21-M02
Source: EMA Published on 2024-09-13
Opinion/decision on a Paediatric investigation plan (PIP): Verzenios, abemaciclib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Oncology, PIP number: P/0313/2023
Source: EMA Published on 2024-09-13
Opinion/decision on a Paediatric investigation plan (PIP): Verzenios, abemaciclib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Oncology, PIP number: P/0312/2023
Source: EMA Published on 2024-09-13
Opinion/decision on a Paediatric investigation plan (PIP): Lynparza, Olaparib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Oncology, PIP number: P/0320/2023
Source: EMA Published on 2024-09-13
Opinion/decision on a Paediatric investigation plan (PIP): Leqvio, Inclisiran sodium, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Endocrinology-Gynaecology-Fertility-Metabolism, PIP number: P/0322/2023
Source: EMA Published on 2024-09-13
Opinion/decision on a Paediatric investigation plan (PIP): Imjudo, Tremelimumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Oncology, PIP number: P/0302/2023
Source: EMA Published on 2024-09-13
Opinion/decision on a Paediatric investigation plan (PIP): Imfinzi, durvalumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Oncology, PIP number: P/0301/2023
Source: EMA Published on 2024-09-13
Opinion/decision on a Paediatric investigation plan (PIP): Namuscla, Mexiletine hydrochloride, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Other, PIP number: P/0300/2023
Source: EMA Published on 2024-09-13

Know Which Medication Is Right for Your Seasonal Allergies
Source: FDA Published on 2024-06-25
Sani-Care Salon Products, Inc. - 673747 - 04/24/2024
Source: FDA Published on 2024-06-25
Glenmark Pharmaceuticals Inc., USA Issues Voluntary Nationwide Recall for Potassium Chloride Extended-Release Capsules, USP (750 mg) 10 mEq K Due to Failed Dissolution
Source: FDA Published on 2024-06-25
Report | Drug Shortages: Root Causes and Potential Solutions
Source: FDA Published on 2024-06-24
FDA approves treatment for chronic inflammatory demyelinating polyneuropathy (CIDP) in adults
Source: FDA Published on 2024-06-24
Facilitating Generic Drug Product Development through Product-Specific Guidances - 04/25/2024
Source: FDA Published on 2024-06-24
Modernizing the New Drugs Regulatory Program
Source: FDA Published on 2024-06-24
FDA grants accelerated approval to adagrasib with cetuximab for KRAS G12C-mutated colorectal cancer
Source: FDA Published on 2024-06-21
Public Workshop: Best Practices for Meeting Management Under PDUFA VII - 07/22/2024
Source: FDA Published on 2024-06-21
Center for Drug Evaluation and Research National Survey on Numerical Claims in Prescription Drug Advertising
Source: FDA Published on 2024-06-20
Infla-650 contains hidden drug ingredients
Source: FDA Published on 2024-06-20
Cefdinir - Oral products
Source: FDA Published on 2024-06-20
Considerations in Demonstrating Interchangeability With a Reference Product: Update
Source: FDA Published on 2024-06-20
Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug or Device Inspection
Source: FDA Published on 2024-06-20
FDA updates guidance on interchangeability
Source: FDA Published on 2024-06-20

Class 3 Medicines Recall: Theramex HQ UK Ltd, Evorel Sequi, EL (24)A/41
Source: MHRA Published on 2024-09-12
Field Safety Notices: 2 to 6 September 2024
Source: MHRA Published on 2024-09-06
Field Safety Notices: 26 to 30 August 2024
Source: MHRA Published on 2024-09-04
CPT Hip System Femoral Stem 12/14 Neck Taper: Increased Risk of Postoperative Periprosthetic Femoral Fracture, DSI/2024/007
Source: MHRA Published on 2024-09-04
Philips Respironics BiPAP A series ventilators: alarm malfunction and risk of therapy interruptions in ventilators not intended for life-support, DSI/2024/006
Source: MHRA Published on 2024-08-28
Class 4 Medicines Defect Information: Chemidex Pharma Ltd, Ponstan 250mg Capsules & 500mg Tablets (mefenamic acid), EL(24)A/40
Source: MHRA Published on 2024-08-27
Field Safety Notices: 19 to 23 August 2024
Source: MHRA Published on 2024-08-27
Field Safety Notices: 12 to 16 August 2024
Source: MHRA Published on 2024-08-19
Class 3 Medicines Recall: Glenmark Pharmaceuticals Europe Ltd, Fingolimod 0.5 mg Hard Capsules, EL(24)A/39
Source: MHRA Published on 2024-08-19
Field Safety Notices: 5 to 9 August 2024
Source: MHRA Published on 2024-08-16
Class 2 Medicines Recall: Strides Pharma UK Limited, Loperamide Hydrochloride Capsules 2mg, EL(24)A/38
Source: MHRA Published on 2024-08-15
Class 4 Medicines Defect Information: Dawa Limited, Trazodone Hydrochloride 50mg, 100mg Capsules & 50mg/5ml Oral Solution, EL (24)A/37
Source: MHRA Published on 2024-08-14
Class 4 Medicines Notification, Star Pharmaceuticals Limited, Diflucan Oral Suspension 40mg/ml, EL(24)A36
Source: MHRA Published on 2024-08-12
Class 3 Medicines Recall: Accord-UK Ltd, Trandolapril 0.5mg, 2mg, 4mg Capsules, EL(24)A/35
Source: MHRA Published on 2024-08-08
Class 4 Medicines Defect Information: Sandoz Limited, Omeprazole products, EL(24)A/34
Source: MHRA Published on 2024-08-07

FDA

Know Which Medication Is Right for Your Seasonal Allergies
Source: FDA Published on 2024-06-25
Sani-Care Salon Products, Inc. - 673747 - 04/24/2024
Source: FDA Published on 2024-06-25
Glenmark Pharmaceuticals Inc., USA Issues Voluntary Nationwide Recall for Potassium Chloride Extended-Release Capsules, USP (750 mg) 10 mEq K Due to Failed Dissolution
Source: FDA Published on 2024-06-25
Report | Drug Shortages: Root Causes and Potential Solutions
Source: FDA Published on 2024-06-24
FDA approves treatment for chronic inflammatory demyelinating polyneuropathy (CIDP) in adults
Source: FDA Published on 2024-06-24
Facilitating Generic Drug Product Development through Product-Specific Guidances - 04/25/2024
Source: FDA Published on 2024-06-24
Modernizing the New Drugs Regulatory Program
Source: FDA Published on 2024-06-24
FDA grants accelerated approval to adagrasib with cetuximab for KRAS G12C-mutated colorectal cancer
Source: FDA Published on 2024-06-21
Public Workshop: Best Practices for Meeting Management Under PDUFA VII - 07/22/2024
Source: FDA Published on 2024-06-21
Center for Drug Evaluation and Research National Survey on Numerical Claims in Prescription Drug Advertising
Source: FDA Published on 2024-06-20
Infla-650 contains hidden drug ingredients
Source: FDA Published on 2024-06-20
Cefdinir - Oral products
Source: FDA Published on 2024-06-20
Considerations in Demonstrating Interchangeability With a Reference Product: Update
Source: FDA Published on 2024-06-20
Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug or Device Inspection
Source: FDA Published on 2024-06-20
FDA updates guidance on interchangeability
Source: FDA Published on 2024-06-20

Biosimilar-main-slider

Upcoming Events

News &
Events

Explore

Drag